Jane Street
ELOS

Jane Street’s Syneron Medical Ltd ELOS Stock Holding History

Jane Street’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-85,400
Closed -$717K – 5040
2016
Q4 		$717K Buy
+85,400
New +$669K ﹤0.01% 2463

Other funds holding ELOS

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
DGHMC
Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Jane Street's ELOS Position: Q2 2017 in Review

Jane Street sold out of Syneron Medical Ltd (ELOS) in Q2 2017, closing a stake of 10,373 shares — an estimated $109K sold.

Jane Street first reported a position in ELOS in Q4 2013 and held it in 3 quarters. The position peaked at $230K in Q4 2016. 79 funds tracked by Wall St. Rank hold ELOS as of Q2 2017.

  • Jane Street reported no remaining Syneron Medical Ltd position as of Q2 2017 after selling out during the quarter.
  • Jane Street sold 10,373 Syneron Medical Ltd shares in Q2 2017, an estimated $109K.
  • Jane Street first reported a position in Syneron Medical Ltd in Q4 2013 and held it in 3 quarters.
  • Jane Street's Syneron Medical Ltd position peaked at $230K in Q4 2016.
  • 79 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q2 2017.

Based on Jane Street's 13F filing for Q2 2017, filed 14 Aug 2017.